Mylan Laboratories Inc — lobbying record — Receipts Report
Client
Lobbying client · LD-2 disclosures
Mylan Laboratories Inc
Pennsylvania
50 filings from 3 registrants · 2008–2014 · latest filed Jan 20, 2015
Reported on its behalf
$2.9M
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$2.9M
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: mylan-laboratories-inc.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
CSP
8 filings
$750K on those filings
Pharmacy
PHA
8 filings
$750K on those filings
Torts
TOR
8 filings
$440K on those filings
Foreign Relations
FOR
7 filings
$430K on those filings
Budget/Appropriations
BUD
7 filings
$390K on those filings
Taxation/Internal Revenue Code
TAX
2 filings
$120K on those filings
Government Issues
GOV
1 filing
$90K on those filings
Medicare/Medicaid
MMM
1 filing
$90K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
113th Congress
School Access to Emergency Epinephrine Act
9 filingsthrough 2014
H.R. 460113th CongressPatients' Access to Treatments Act of 20139 filingsthrough 2014
H.R. 486113th CongressStop Tampering of Prescription Pills Act of 20139 filingsthrough 2014
H.R. 8113th CongressReserved for the Speaker.9 filingsthrough 2014
S. 214113th CongressPreserve Access to Affordable Generics Act9 filingsthrough 2014
S. 504113th CongressFAIR Generics Act9 filingsthrough 2014
S. 621113th CongressSafe Prescribing Act of 20139 filingsthrough 2014
S. 957113th CongressDrug Supply Chain Security Act9 filingsthrough 2014
S. 959113th CongressPharmaceutical Quality, Security, and Accountability Act9 filingsthrough 2014
H.R. 3177113th CongressPEPFAR Stewardship and Oversight Act of 20134 filingsthrough 2014
S. 1013113th CongressPatent Abuse Reduction Act of 20134 filingsthrough 2014
S. 1545113th CongressPEPFAR Stewardship and Oversight Act of 20134 filingsthrough 2014
S. 1720113th CongressPatent Transparency and Improvements Act of 20134 filingsthrough 2014
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
through 2014
Shimon SteinBlank Rome Government RelationsCovered position: Intern, Rep. Robert Aderholt12 filingsthrough 2014
JOHN J MCGOVERN jrMcgovern & Smith, LLC11 filingsthrough 2011
Hana GreenbergBlank Rome Government RelationsCovered position: Legislative Aide, Sen. Chuck Schumer5 filingsthrough 2014
